Home' Trinidad and Tobago Guardian : July 7th 2014 Contents A36
body & soul
Guardian www.guardian.co.tt Monday, July 7, 2014
A key player in the oil and gas industry focused on international operations and is one of
the largest on-shore producers in Trinidad is seeking two (2) qualified nationals and/or
residents to fill the position of:
MAJOR ROLES & RESPONSIBILITIES
Monitor, analyze and improve the current drilling and completion methods
Monitor and control cost, down time and other operational inefficiecies
Preparation of risk assessments and hazard analysis for optimizing the operations
Assist with the planning of workload, work scheduling and logistics management,
succession planning, equipment and material allocation
Assist with the preparation of the purchase requets and JAR approval
Support operations with KPI allocations, ISO and quality control, and monthly and
QUALIFICATIONS & EXPERIENCE
Typically 5 - 10 years of related industry experience with B.Sc. degree in Engineering,
with at least 5 years experience at a senior level
Excellent management, contractual and operation skills
Exceptional interpersonal and communication skills with the ability to handle multiple
Highly organized with strong analytical skills and attention to detail.
Copies of all supporting documents must be attached to the application and
submitted no later than July 9, 2014.
Human Resources Department
Touchstone Exploration (Trinidad) Ltd.
# 30 Forest Reserve Road
Trinidad West Indies
A copy of your application and resume should also be forwarded to:
Chief Manpower Officer
Ministry of Labour and Small and Micro Enterprise Development
Level 11, Riverside Plaza, Besson Street
Port of Spain
UNSUITABLE APPLICATIONS WILL NOT BE ACKNOWLEDGED
The World Health Organization (WHO) launched
an ambitious plan for rich countries to sharply
reduce tuberculosis infections and serve as a model
for harder-hit countries of Africa and Asia, where
the disease still thrives.
Although the 33 targeted countries, 21 of them in
Europe, have relatively low rates of infection, the
disease still kills 10,000 people a year there---pre-
dominantly homeless people, migrants, prisoners,
drug users, heavy drinkers or people with HIV/Aids---
the WHO said.
It is in these communities that industrialised coun-
tries including the United States could pilot approaches
to a disease that is both preventable and curable that
could then be transferred to poorer countries, Dr
Mario Raviglione, director of the WHO s Global TB
Programme, told a news briefing.
The goal is to reduce the infection rate by a factor
of ten to fewer than ten new TB cases per million
people per year by 2035 in each of the 33 countries,
and to effectively eliminate it by 2050.
"We are after, really, is finding what we call trail-
blazers or model countries that would embark in a
resolute way on this campaign against tuberculosis,
proving that it is indeed possible to get to elimination
level," Raviglione said.
The WHO strategy involves broader screening for
both active and latent TB infections in high-risk
groups, funding high-quality health services, and
investing in new drugs, vaccines and diagnostic tests.
Common symptoms of TB are coughing with spu-
tum and blood at times, chest pains, weakness, weight
loss and fever. But the disease, which is transmitted
through the air, can take years to develop, and it is
also vital to test as early as possible to determine if
a person has a drug-resistant form.
Of the 155,000 annual new cases of tuberculosis
in the target countries, about 500 are multi-drug
resistant (MDR-TB), caused by an extreme superbug
form of the bacterium that does not respond to the
most powerful first-line drugs.
But worldwide, China, India and South Africa are
among the hardest hit by TB.
The WHO estimates that 8.6 million people devel-
oped TB in 2012 and 1.3 million died. Some 450,000
fell ill with dangerous superbug strains in 2012, and
up to two million people worldwide may be infected
with drug-resistant TB by 2015, it says.
Raviglione said that Belarus and parts of Russia
had high rates of MDR, which he called a "disaster
situation". Migrants from countries of the former
Soviet Union who carry the infection could pose a
threat to Western Europe, he added.
Standard treatment for TB usually includes a mix
of four antibiotic drugs over a period of six months.
MDR-TB can take 18 to 24 months to treat and cost
up to $100,000 in rich countries.
But research efforts are already bearing some fruit.
Raviglione said about 12 promising vaccines were
being tested, mostly by US or UK companies, and
some could be on the market by 2022.
The first new TB treatment in more than 40 years,
Johnson & Johnson s bedaquiline, was approved in
2012 for use on drug-resistant TB, and in 2013 the
European Medicines Agency recommended granting
conditional marketing approval for delamanid, a
treatment for MDR being developed by Japan s Otsuka.
YOUR DAILY HEALTH
News and Advice
rich nations to
step up fight
A tuberculosis patient looks on as he rests at the Rajan Babu
Tuberculosis Hospital in New Delhi in March. AFP PHOTO
Links Archive July 5th 2014 July 8th 2014 Navigation Previous Page Next Page